• 1
    Harlow BL, Vitonis AF, Sparen P, Cnattingius S, Joffe H, Hultman CM. Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without prior pre pregnancy or prenatal psychiatric hospitalizations. Arch Gen Psychiatry 2007; 64: 428.
  • 2
    Ververs FF, Kaasenbrood H, Visser GH, Schobben AF, De Jong-van den Berg L, Egberts AC. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62: 86370.
  • 3
    Bakker MK, Kolling P, Van Den Berg PB, De Walle HE, De Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65: 6006.
  • 4
    Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hen drick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499507.
  • 5
    Wadhwa PD, Sandman CA, Porto M, Dunkel-Schetter C, Garite TJ. The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investiga tion. Am J Obstet Gynecol 1993; 169: 85865.
  • 6
    Maina G, Saracco P, Giolito MR, Danelon D, Bogetto F, Todros T. Impact of maternal psychological distress on fetal weight, prematurity and intrauterine growth retardation. J Affect Disord 2008; 111: 21420.
  • 7
    Murray L, Sinclair D, Cooper P, Ducourmau P, Turner P, Stein A. The socioemotional devel opment of 5-year-old children of postnatally depressed mothers. J Child Psychol Psychiatry 1999; 40: 125971.
  • 8
    Murray L, Fiori-Cowley A, Hooper R, Cooper PJ. The impact of postnatal depression and associated adversity on early mother-infant interactions and later infant outcome. Child Dev 1996; 67: 251226.
  • 9
    Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160: 1736.
  • 10
    Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 237283.
  • 11
    Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anesth Analg 1953; 32: 2607.
  • 12
    Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assess ment and management. Addict Dis 1975; 2: 14158.
  • 13
    De Moor RA, Mourad L, Ter Haar J, Egberts AC. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd 2003; 147: 18856; author reply 1886.
  • 14
    Pakalapati RK, Bolisetty S, Austin MP, Oei J. Neonatal seizures from in utero venlafaxine ex posure. J Paediatr Child Health 2006; 42: 7378.
  • 15
    Mohan CG, Moore JJ. Fluoxetine toxicity in a preterm infant. J Perinatol 2000; 20: 4456.
  • 16
    Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J (Clin Res Ed) 1982; 284: 18378.
  • 17
    Ahmed M, Parameshwaran A, Swamy P. Neonatal convulsions secondary to paroxetine withdrawal. J Pak Med Assoc 2007; 57: 162.
  • 18
    Ververs FFT. Antidepressants during pregnancy Risks for mother and child. Thesis. Utrecht University; 2009.